Mills GB

No ORCID on file · 10 papers in corpus · active 1998-2024

Study types

  • other 1
  • review 1

Condition tags

  • endometriosis 2
2024
Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression.
JCO precision oncology ·doi:10.1200/po.23.00686

Case report of a HER2-expressed ovarian clear cell carcinoma with exceptional response to trastuzumab deruxtecan.

2020
Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer.
American journal of cancer research

The AT-rich Interactive Domain 1A (ARID1A) is one of the most frequently mutated genes in gastric cancer. Here, we found that genetic variants in noncoding regions of ARID1A associated with altered protein levels by target sequencing. Notab…

other 2014
A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation
BMC cancer ·doi:10.1186/1471-2407-14-120

BACKGROUND: Ovarian cancer is now recognized as a number of distinct diseases primarily defined by histological subtype. Both clear cell ovarian carcinomas (CCC) and ovarian endometrioid carcinomas (EC) may arise from endometriosis and freq…

2014
Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.
Cancer cell ·doi:10.1016/j.ccell.2014.08.017

PIK3R1 (p85α regulatory subunit of PI3K) is frequently mutated across cancer lineages. Herein, we demonstrate that the most common recurrent PIK3R1 mutation PIK3R1(R348∗) and a nearby mutation PIK3R1(L370fs), in contrast to wild-type and mu…

2013
Repurposing the Pap smear: one step closer to gynecologic cancer screening.
Science translational medicine ·doi:10.1126/scitranslmed.3005411

Prevention and early detection remain essential to decreasing cancer mortality. Screening DNA in Pap smears has the potential to increase the rate of early detection of endometrial and ovarian cancers. In this issue of Science Translational…

2011
Rethinking ovarian cancer: recommendations for improving outcomes.
Nature reviews. Cancer ·doi:10.1038/nrc3144

There have been major advances in our understanding of the cellular and molecular biology of the human malignancies that are collectively referred to as ovarian cancer. At a recent Helene Harris Memorial Trust meeting, an international grou…

2010
Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid.
Molecular cancer ·doi:10.1186/1476-4598-9-140

BackgroundAlthough the incidence of melanoma in the U.S. is rising faster than any other cancer, the FDA-approved chemotherapies lack efficacy for advanced disease, which results in poor overall survival. Lysophosphatidic acid (LPA), autota…

2009
The biology of ovarian cancer: new opportunities for translation.
Nature reviews. Cancer ·doi:10.1038/nrc2644

Over the past two decades, the 5-year survival for ovarian cancer patients has substantially improved owing to more effective surgery and treatment with empirically optimized combinations of cytotoxic drugs, but the overall cure rate remain…

2008
Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead.
Advances in experimental medicine and biology ·doi:10.1007/978-0-387-69080-3_3
review 1998
CA 125: the past and the future
The International journal of biological markers ·doi:10.1177/172460089801300402

Over the last 15 years, substantial progress has been made in understanding the potential and the limitations of the CA 125 assay. More than 2000 papers have been published concerning laboratory and clinical studies of CA 125. The original …